期刊文献+

索拉非尼联合阿霉素经肝动脉化疗栓塞治疗晚期肝癌临床观察 被引量:2

Clinical Observation of Sorafenib Combined with Adriamycin Transcatheter Arterial Chemoembolization to Treat Advanced Hepatocellular Carcinoma
下载PDF
导出
摘要 目的观察索拉非尼联合阿霉素经肝动脉化疗栓塞(TACE)治疗晚期肝细胞肝癌(HCC)的临床疗效和毒性反应。方法选取病理证实符合观察标准且获随访的晚期HCC患者18例,治疗过程中每4~6周评价疗效和毒性反应,并随访中位至疾病进展时间和中位总生存期。结果随访时间内索拉非尼联合阿霉素TACE治疗的晚期HCC患者中位至疾病进展时间6.1个月,中位总生存期13.2个月;索拉非尼相关毒性反应主要为手足皮肤反应、腹泻、高血压和乏力,经对症处理后绝大多数得到缓解。结论索拉非尼联合阿霉素TACE治疗晚期HCC安全、有效。 Objective To investigate the therapeutic effect and adverse reaction of sorafenib combined with adriamycin transcatheter arterial chemoembolization(TACE)to treat advanced gepatocellular carcinoma(HCC).Methods According to the test criteria,18 patients with advanced HCC who was pathologically confirmed or clinically diagnosed were visited.The therapeutic effect and adverse reaction were evaluated every 4-6 weeks,and the median time to progression and the median overall survival time were followed up in the same time.Results In the follow-up period,the median time to progression was 6.1 months,and the median overall survival time was 13.2 months.The most common adverse events were hand foot skin reaction,diarrhea,hypertension and feeble,most of them were released after treatment.Conclusions It is safe and effective to administer sorafenib combined TACE with ADM in advanced HCC.
出处 《医学综述》 2012年第3期473-474,共2页 Medical Recapitulate
关键词 索拉非尼 阿霉素 肝动脉化疗栓塞 肝细胞肝癌 Sorafenib Adriamycin Transcatheter arterial chemoembolization Hepatocelluar carcinoma
  • 相关文献

参考文献9

  • 1杨秉辉,丛文铭,周晓军,陈孝平,杨甲梅,樊嘉,王建华,杨仁杰,李槐,蒋国梁,曾昭冲,陈敏华,陈敏山,梁萍,吕明德,罗荣城,刘鲁明,秦叔逵,叶胜龙,吴孟超,汤钊猷,孙燕,管忠震.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3):259-269. 被引量:313
  • 2Llovet JM,Bruix J.Molecular targeted therapies in hepatocellular carcinoma[J].Hepatology,2008,48(4):1312-1327.
  • 3Pang RW,Poon RT.Frommolecularbiology to targeted therapies for hepatocellular carcinoma:the future is now[J].Oncology,2007,72(Suppl 1):30144.
  • 4Abou-Alfa GK,Schwartz L,Ricci S,et al.Phase Ⅱ study of sorafenib in patientswith advanced hepatocellular carcinoma[J].J Clin Oncol,2006,24(26):4293-4300.
  • 5Llovet JM,Ricci S,Mazzaferro V.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
  • 6Chang YS,Adnane J,Trail PA,et al.Sorafenib(BAY 43-9006)inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograftmodels[J].Cancer Chemother Pharmacol,2007,59(5):561-574.
  • 7Zhu AX.Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma[J].Cancer,2008,112(2):250-259.
  • 8Sergio A,Cristofori C,Cardin R,et al.Transcatheter arterial chemoembolization(TACE)in hepatocellular carcinoma(HCC):The role of angiogenesis and invasiveness[J].Am J Gastroenterol,2008,103(3):914-921.
  • 9Abou-Alfa GK,Johnson P,Knox JJ,et al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma[J].JAMA,2010,304(19):2154.

共引文献312

同被引文献31

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部